Spectral MD posts loss as it develops wound care products

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Wound-care technology group Spectral MD posted a first-half loss as it continued to commercialise it products.

Pre-tax losses for the six months through June amounted to £0.88 million, compared to a year-on-year profit of £1.72 million. Revenue was broadly steady at £7.0 million.

'We have exceeded the commercial milestones we set for the company in our admission document,' chief executive Wensheng Fan said.